Section Arrow
MENS.NASDAQ
- Jyong Biotech Ltd
Quotes are at least 15-min delayed:2026/01/05 07:20 EST
Pre Market
Last
 3.62
+0.21 (+6.16%)
Bid
3.54
Ask
3.7
High 3.73 
Low 3.5 
Volume 1.77K 
Regular Hours (Closed)
Last
 3.41
-0.54 (-13.67%)
Day High 
4.19 
Prev. Close
3.95 
1-M High
30.455 
Volume 
668.72K 
Bid
3.54
Ask
3.7
Day Low
3.41 
Open
4.09 
1-M Low
2.601 
Market Cap 
327.68M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.6 
20-SMA 14.84 
50-SMA 29.96 
52-W High 67 
52-W Low 2.601 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.04/--
Enterprise Value
338.37M
Balance Sheet
Book Value Per Share
-0.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
Pre Market 0.6991 +0.0391 +5.92%
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
Pre Market 0.5413 +0.0309 +6.05%
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
Pre Market 4.71 +0.36 +8.28%
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
Pre Market 0.1438 +0.0069 +5.04%
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Pre Market 4.28 +0.08 +1.90%
Industry overview quotes are at least 15 minutes delayed
Business Description
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.